29 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 104

Rhino Rescue Launches New Outdoor Product Lineup to Enhance Safety for Adventurers

LOS ANGELES, April 17, 2025 /PRNewswire/ — Rhino Rescue, a global leader in emergency preparedness solutions, recently launched its latest innovations: the Rhino Rescue Mini First Aid Kit, a compact yet comprehensive emergency kit specifically designed for high-activity outdoors, the Home First Aid Kit specifically designed for home and office use, and the Outdoor Camping First Aid Kit designed for campers and outdoor families.

photos from collaborating influencer
photos from collaborating influencer

This marks a significant step in Rhino Rescue’s expansion into the consumer market, following overwhelming demand from its community. Officially launched in late 2024, the brand’s new civilian product line is tailored for outdoor sports, travel, and home emergency preparedness—bringing tactical-grade emergency care into everyday life.

Addressing a Growing Need

According to the National Safety Council, over 3.7 million injuries requiring emergency care in 2023 were related to sports and recreational equipment. Meanwhile, a report by the American Red Cross revealed that 80% of household first aid kits are either incomplete or contain expired items.

Rhino Rescue’s new range of products addresses this critical safety gap with accessible, specialized solutions for a variety of real-life scenarios.

Product Highlights

Mini First Aid Kit

Designed for hiking, cycling, and off-road sports, this compact kit includes all essentials while remaining portable:

  • Premium Material: Weighing just 20g, it’s made from high-quality nylon for durability.
  • Ultralight & Compact: Measuring 180×100×30mm and weighing 0.45lb when fully equipped, it easily fits in any bag or backpack.
  • Comprehensive Supplies: Contains 79 emergency essentials for treating minor wounds, cuts, scrapes, burns, colds, and blisters.

In just two weeks, its Facebook video gained over 30,000 views, with users calling it “portable and practical,” making it a must-have for outdoor enthusiasts.

Home First Aid Kit

Designed for home, office, and on-the-go use, this 240-piece professional-grade first aid kit is ideal for treating minor injuries, common illnesses, and unexpected emergencies.

  • Comprehensive Coverage: Includes 240 essential items such as a thermometer, antibiotic ointments, burn gel, and cold packs to treat minor injuries and common emergencies.
  • Versatile & Compact: Perfect for homes, offices, schools, dorms, cars, camping, and travel—delivering preparedness in any setting, all in a compact 7.9 x 6.5 x 4.5-inch design.
  • Smart Organization: Features thoughtfully arranged compartments and a removable center layer for quick, easy access to supplies.

“I keep one in my kitchen and one in my car—it’s so well-stocked and easy to use,” says Julia T., a home user.

Outdoor Camping First Aid Kit

Designed for campers and outdoor families, this kit includes essential medical supplies like burn gel, a CPR face shield, splints, and a digital thermometer. It features camping-specific items to address various outdoor injuries without adding extra weight.

Influencer Jamie Curry commented, “My wife was injured during a camping trip, and I didn’t have a single first aid item with me. That’s when I realized how essential these kits are.”

“These products were born directly from user feedback. Our goal is to help every individual—whether in the city or the wilderness—be better prepared. Every second counts during an emergency, and we want to make sure people are ready when it matters most,” said Owen Zhuang, Product Director at Rhino Rescue.

Founded in 2010, Rhino Rescue is a global leader in emergency medical solutions, serving both professional responders and the civilian market. With a mission to make high-quality, tactical-grade emergency tools accessible for everyone, Rhino Rescue is redefining the emergency preparedness experience through professional expertise and user-friendly design.

Wherever you are—urban streets or remote trails—Rhino Rescue has your back.

For more information about the brand, visit the website at: https://rhinorescuestore.com/collection

mini First Aid Kit
mini First Aid Kit

Outdoor Camping First Aid Kit
Outdoor Camping First Aid Kit

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Highlights

  • Clarity has signed a commercial-scale agreement with Nusano, Inc. (“Nusano”) for supply of copper-64 (Cu-64 or 64Cu) isotope.
  • The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.
  • The copper-64 supply from Nusano will complement Clarity’s existing network of US-based suppliers to ensure seamless, abundant production of this diagnostic isotope as the Company is progressing a number of late-stage clinical trials and fast approaching commercialisation.
  • Nusano plans to begin production of other medical isotopes, such as copper-67 and actinium-225, both of which are used in Clarity’s products, in 2025-2026.

SYDNEY, April 17, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop and commercialise next-generation products that improve treatment outcomes for people with cancer, is pleased to announce the signing of a commercial-scale Supply Agreement for copper-64 with Nusano.

Nusano’s 190,000 square foot state-of-the-art facility in West Valley City, Utah is expected to begin production in 2025 with copper-64 isotope supply planned to commence in early 2026. The accelerator-based proprietary technologies employed by Nusano are particularly well suited for cost-effective mass production of copper-64. The Nusano facility is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, well in excess of commercial-scale demands across multiple large oncology indications in line with Clarity’s commercialisation strategy. Nusano is also developing in-house production of the target material for copper-64 manufacturing, nickel-64 (Ni-64), and plans to commence production of copper-67 (Cu-67 or 67Cu) and actinium-225 (Ac-225 or 225Ac) isotopes in 2025-2026. Both of these isotopes are used in Clarity’s pipeline of theranostic products in development.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “The signing of this Supply Agreement with Nusano will complement Clarity’s existing network of US-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope. As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-out of our Targeted Copper Theranostics (TCTs) in the largest healthcare market in the world, the US. This Agreement is an important part of a larger commercial manufacturing strategy, which we will continue implementing as we get closer to the filing of New Drug Applications (NDA) with the US Food and Drug Administration (FDA).

“The ability to make isotopes and products in the US for the treatment of the American people is an important advantage in the current geo-political and economic environment. By building a supply chain that is fully integrated, from high-volume isotope production, to centralised product manufacture, to delivering these ready-to-use diagnostics to imaging sites in every state of the US on time and on demand, we are aiming to build a model that is impervious to economic and political instability.

“In large oncology indications, such as prostate-specific membrane antigen (PSMA) positron emission tomography (PET) diagnostics (which Clarity is addressing with our key product, SAR-bisPSMA), ensuring stable, abundant and seamless supply of isotopes is crucial for a successful commercial launch.

“We have seen first-hand from the current generation of radio-diagnostics that efficient and timely product supply can make or break the adoption of the products and their expansion in the oncology practice. The current market leaders in PSMA PET imaging face several limitations associated with their short half-life (less than 2 hours vs. 12.7 hours for copper-64). These include short shelf-lives, restricted availability throughout the imaging site’s workday, and narrow imaging windows. At Clarity, our strategy is straightforward: we are determined to overcome these limitations and lay a strong foundation for the successful roll-out of TCTs globally.

“Our goal is to take radiopharmaceuticals to the next level by building a reliable and accessible supply that is consistent with the big pharma oncology model and deliver advantages to patients, their treating clinicians and imaging sites. Under this central manufacture model, the imaging sites will receive the copper-64 based diagnostics on demand, at any time and in volumes consistent with the rapidly growing demand of this blockbuster market. The clinicians have the added flexibility to administer the copper-based diagnostics and image patients over a significantly longer timeframe than what the current products allow. This translates into more flexibility for patient imaging and potentially higher lesion detection sensitivity that could lead to better identification of cancer lesions, helping to determine the best course of treatment for oncology patients.

“With our SAR-bisPSMA product generating a lot of exciting data and 3 US FDA Fast Track Designations granted for this product1,2,3 for accelerating its development, locking in commercial-scale supply of copper-64 means we are now closer than ever to changing the paradigm of prostate cancer diagnosis, ensuring no man is left waiting for a PSMA PET scan,” said Dr Taylor.

Nusano’s Chief Executive Officer, Chris Lowe, commented, “Nusano is commercialising a breakthrough radioisotope production platform in 2025 capable of producing more than 25 radioisotopes for life science applications, including copper-64, copper-67 and actinium-225. We are excited to enter into a Supply Agreement with Clarity for copper-64 to enable their clinical and commercial efforts with a dependable supply of radioisotopes from our world-class production facility in Utah.”

Additional Disclosure

The Supply Agreement is effective as of 16 April 2025 and is for an initial period of 3 years with automatic renewal for successive 2-year periods. Cancellation provisions are aligned with industry standard rates.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

About Nusano

Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit nusano.com.

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor     

Catherine Strong

Executive Chairperson

Investor/Media Relations

ataylor@claritypharm.com   

c.strong@morrowsodali.com 

+61 406 759 268

Nusano                                        

Scott Larrivee

Joyce Allaire

Media Relations

Investor Relations

scott.larrivee@nusano.com 

jallaire@lifesciadvisors.com

1-608-345-6629     

1-212-915-2569

References

  1. Clarity Pharmaceuticals. Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA. https://www.claritypharmaceuticals.com/news/fast-track/
  2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/
  3. Clarity Pharmaceuticals. Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA. https://www.claritypharmaceuticals.com/news/ftd-67cu-sarbispsma/

This announcement has been authorised for release by the Executive Chairperson.

Insight Partners Doubles Down on Devicie, a Leader in Microsoft Intune Management

Growth investment to accelerate Devicie’s push to ensure every Microsoft-aligned organization has secure devices and productive teams, without the workload.

TAMPA BAY, Fla., April 17, 2025 /PRNewswire/ — Devicie, a leader in automated and optimized Microsoft Intune Device Management, today announced a growth investment from Devicie insider and global software investor Insight Partners, bolstering its commitment to providing Microsoft-first solutions for end-user organizations and managed service providers (MSPs) globally.

Shane Harding, CEO of Devicie
Shane Harding, CEO of Devicie

“Insight Partners’ reinvestment is a strong endorsement of our mission to seamlessly unlock the power of Intune and ensure every Microsoft-aligned organization has secure devices and productive teams,” says Shane Harding, CEO of Devicie. “This growth investment will enable us to enhance our customers’ success, drive platform and product innovation, and scale our operations to meet the evolving needs of our global market. We are excited and honoured to continue this journey with Insight Partners.”

Microsoft is the global leader in productivity apps, cloud storage, and security, with more than 70% of the Fortune 500 using Microsoft 365, including Intune for device management. Devicie’s multi-tenant solution enables IT teams and MSPs worldwide to transition to a cloud-native state by automating the implementation and ongoing management of Microsoft Intune. With zero-touch configuration, automatic updates, application patching, built-in remediation, and enhanced reporting, Devicie provides secure and efficient endpoint management across Android, Apple iOS, Windows, and macOS devices. This results in greater efficiency, seamless security, improved productivity, and complete visibility. 

“Millions of organizations and MSPs are looking to extract as much value as possible from their Microsoft investments,” says Philine Huizing, Managing Director at Insight Partners and Devicie board member. “Devicie’s Microsoft-first strategy aligns with a large cohort of companies looking to consolidate around the Microsoft stack, leveraging what they have while confidently managing endpoint productivity and security. We’re excited to continue our partnership with Shane and the Devicie team in this next chapter of growth.”

Founded in Sydney Australia, Devicie recently moved its headquarters to Tampa Bay, Florida to better serve the US market and to more closely collaborate with Microsoft as members of both its Microsoft for Startups Pegasus Program and Microsoft Intelligent Security Association (MISA).

About Insight Partners
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of September 30, 2024, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

About Devicie
Devicie provides automated, always-optimized Intune deployment and maintenance at scale. Devicie’s approach to an optimal state of modern management – featuring zero-touch configuration, advanced security, and compliance capabilities – transforms Intune adoption and maximizes Microsoft 365 utilization, all without the workload. By fostering synergy between Security and IT departments, as well as empowering CSPs and partners, Devicie emerges as a vital asset for contemporary organizations and partners striving to streamline IT operations and amplify productivity on an international scale. Its established distribution relationships with companies like TD SYNNEX, Microsoft and Crayon make Devicie solutions easily available to MSPs, Microsoft Cloud Solution Providers and end organizations. For further details, visit www.devicie.com.

Product or service names mentioned herein may be the trademarks of their respective owners.

Photo – https://mma.prnasia.com/media2/2666714/Devicie__Shane_Harding__CEO_of_Devicie.jpg?p=medium600

Logo – https://mma.prnasia.com/media2/2666713/Devicie__Logo.jpg?p=medium600

NAB Show Recognizes Saramonic’s Wireless Microphone Advances with Multiple Industry Awards

LAS VEGAS, April 17, 2025 /PRNewswire/ — Saramonic, a global leader in professional audio technology, announced today that its latest wireless microphone systems received multiple industry recognitions at the 2025 NAB Show. Among the most notable awards, the Saramonic Ultra was named Product of the Year 2025 by the NAB Show, and the newly launched K9 Dual-Channel UHF Wireless Microphone System was recognized with a Best of Show Award from CineD, a leading authority in cinematography and filmmaking technology, and awarded the Best of Show distinction by TVTech, a preeminent television and broadcast technology authority.


These distinctions reflect Saramonic’s continued commitment to delivering high-performance, feature-rich solutions that meet the evolving needs of broadcast professionals, content creators, and production teams worldwide.

Engineered to offer professional-grade reliability and flexibility, the Saramonic K9 integrates ultra-wide UHF transmission, 32-bit float onboard recording, timecode synchronization, and a dual-display interface in a compact and cost-efficient form. The system is designed for creators who demand uncompromising audio quality in fast-paced production environments.

The Saramonic Ultra, awarded by NAB Show as one of the most innovative products in the industry, delivers advanced functionality and robust performance to support modern storytelling workflows. The award recognizes products that demonstrate excellence in engineering, innovation, and practical application across the media, entertainment, and broadcast sectors.

A Decade of Audio Innovation

Since its establishment in 2012, Saramonic has become known for redefining the boundaries of professional audio through continuous innovation. The company has introduced a series of industry firsts, including the world’s first 3-channel Hi-Fi wireless microphone, the first dual-channel 2.4GHz system, and the first wireless microphone featuring a touchscreen interface.

Saramonic’s core technological capabilities include advanced microphone array design, AI-powered noise cancellation, automatic gain control (AGC), acoustic echo cancellation (AEC), virtual surround sound (5.1 and 7.1), and proprietary audio compression algorithms. These technologies are foundational to the company’s comprehensive product ecosystem, which spans wireless microphone systems, studio microphones, shotgun mics, intercom solutions, and tools for broadcast and content creation.

With over 400 patents, five acoustic labs, and a global user base across 132 countries and regions, Saramonic continues to invest in R&D and expand its product offerings to serve the audio demands of professionals across industries.

For more information, visit www.saramonic.com

Instagram: Instagram.com/saramonic_global

Facebook: facebook.com/SaramonicOfficial

LinkedIn: linkedin.com/company/saramonic-official

t’order Launches $50M Series C to Scale Data-Driven Foodservice Tech and Accelerate Global Expansion

SEOUL, South Korea, April 17, 2025 /PRNewswire/ — t’order, a leader in the Korean restaurant tech space, has officially launched its Series C fundraising round, targeting $50 million USD from both domestic and global investors. While the identities of participating institutions remain undisclosed, the round has attracted significant interest from a range of investors, including leading venture capital firms, private equity firms, and financial institutions. To guide the process, t’order has appointed Samil PwC (PricewaterhouseCoopers Korea), the nation’s largest accounting and advisory firm, as its exclusive financial advisor.

t'order CI
t’order CI

Founded in 2019, t’order has quickly become Korea’s leading table-ordering platform, transforming the dining experience with its cutting-edge, fully digital ordering and payment system. The company has installed over 260,000 tablets nationwide, driving a monthly GMV (gross merchandise volume) exceeding $317 million USD, positioning itself as a dominant force in Korea’s restaurant tech sector. With more than $7.4 billion USD in cumulative transaction volume processed to date, t’order is poised for continued growth and innovation.

Currently valued at approximately $220 million USD, t’order has evolved into a comprehensive digital operating system for restaurants, driving significant improvements in operational efficiency, unlocking new revenue streams, and enhancing the overall customer experience. t’order has successfully completed integrations with major POS providers Toast and Clover, paving the way for its U.S. market entry. These integrations provide a seamless experience for North American restaurant operators and chains, further strengthening t’order’s position in the global market.

A key growth driver for t’order is its in-tablet advertising business, which delivers over 3 billion ad impressions monthly across more than 25 million orders. This advertising channel is gaining significant attention as a powerful offline medium, engaging customers during the average 85-minute dwell time at restaurant tables. t’order is also collaborating with large enterprise advertisers to develop real-time, data-driven ad campaigns based on factors such as table size, product type, location, and demographic profiles, ushering in a new era of targeted in-venue marketing.

In 2024, t’order raised $23 million USD in its Series B round, backed by Korea Development Bank, LB Investment, No & Partners, and Eugene Investment & Securities. The funds were used to accelerate product innovation, develop advanced table-ordering devices, enhance R&D for AI-driven personalization and data analytics, and scale nationwide deployment.

With this Series C round, t’order aims to strengthen its leadership in Korea while expanding into new verticals and international markets. Leveraging its extensive dataset, the company plans to provide personalized insights and decision-support tools to restaurateurs, solidifying its position as a category-defining player in global foodservice tech.

SODI Launches Innovative Aroma Scent Phone Case on Kickstarter — Blending Technology with Scented Emotion

SHENZHEN, China, April 17, 2025 /PRNewswire/ — SODI, the premium Apple accessories brand, has just launched a groundbreaking new product on Kickstarter: the Aroma Scent Phone Case, an innovative iPhone case that combines emotional design, everyday functionality, and a touch of luxury.

Exclusively designed for the iPhone 16 Pro and iPhone 16 Pro Max, this case does more than just protect your device — it enhances your daily experience through scent. Inside the case is a discreet, replaceable capsule that releases a gentle fragrance as you use your phone. There are currently five signature scents available, making your phone feel more personal and mood-matching than ever before.

  • Blue Poppy: A rich and intoxicating blend of orange, coffee, and rose in the top notes, balanced with jasmine, lily of the valley, and sandalwood in the middle, and a warm base of amber and musk.
  • Red Rose: A romantic floral symphony with citrus and green freshness at the top, red rose and violet in full bloom at the heart, and soft honey and musk whispering at the base.
  • Earth: A grounding fragrance inspired by nature and the five elements, combining mineral freshness and woody tones with bright hints of grapefruit and orange.
  • Seaside: Crisp citrus and green notes unfold into a bouquet of jasmine, orange blossom, rose, and lily of the valley — evoking the elegance of nature and ocean air.
  • Jasmine: A fresh, floral escape with tuberose, jasmine, and orange blossom, enhanced by sea breeze undertones that transport you to a serene coastal afternoon.

Protection is still top of mind. The case features airbag-style shock resistance, giving your iPhone enhanced drop protection without sacrificing style. It’s also MagSafe compatible, meaning it works perfectly with magnetic mounts, wireless chargers, and accessories — offering seamless convenience without needing to remove the case.

Despite being live on Kickstarter for just two days, the Aroma Scent Phone Case has already drawn significant attention from tech lovers and lifestyle enthusiasts who crave something fresh and meaningful in their everyday carry.

“We wanted to design something that not only protects your phone but also elevates your daily interaction with it,” said a spokesperson for SODI. “The Aroma Scent Case lets users express their personality in a new way — through scent.”

This launch is another example of SODI’s dedication to design that bridges beauty and practicality. Known for accessories like foldable keyboards, laptop stands, and Vision Pro gear, SODI continues to push boundaries in the Apple accessory space.

The Kickstarter campaign is now live, and early supporters can take advantage of exclusive discounts and bundles.

Check out the campaign here: https://www.kickstarter.com/projects/1311812199/sodi-capsule-fragrance-phone-case

About SODI

SODI is dedicated to creating high-performance accessories for Apple users who value innovation, comfort, and style. We stand by sustainability, prioritizing eco-friendly materials and ergonomic designs that seamlessly integrate into your lifestyle. We craft products that blend aesthetic elegance with uncompromising performance, an approach that earned us the prestigious Red Dot Awardand reflects our commitment to smart, sustainable design.

We believe in the power of smart, simple solutions for modern living. Back us today and be part of the next wave of cutting-edge innovations.

  • Core team has over 10+ years combined experience
  • Targeting 20M+ Users Across Europe & North America
  • 200+ invention patents
  • Red Dot Design Award winner
  • Products certified by ISO 9001, CE, RoHS, WEEE, FCC, and China CCC
  • Adjustable Stand, Keyboard, Mouse, iPhone Case, Cable, Wireless Charger, Power Bank, MagSafe Accs.

For media or commercial inquiries, visit our official website at sodigear.com.

Linkind by AiDot Reveals SL5C Smart Solar Spotlight, Revolutionizing Outdoor Lighting with Improved Poor-Weather Charging

It’s the world’s first Smart Solar Spotlight with MPPT charging controller technology for up to 89.9% charging efficiency.

LOS ANGELES, April 17, 2025 /PRNewswire/ — Linkind, a brand of AiDot, officially announces the launch of the SL5C, the world’s first smart solar spotlight equipped with Maximum Power Point Tracking (MPPT) technology. Now available at Linkind.com, the SL5C enhances solar charging efficiency beyond industry standards, ensuring reliable and uninterrupted lighting even in cloudy or rainy conditions.

Revolutionizing Solar Lighting with Advanced MPPT Technology

The Linkind SL5C sets a new benchmark in solar-powered outdoor lighting by integrating Maximum Power Point Tracking (MPPT)—an advanced solar optimization technology that intelligently adjusts power output based on sunlight conditions. Unlike traditional solar lights that struggle in cloudy or low-light environments, the SL5C maximizes charging efficiency, achieving an industry-leading rate of 89.9%—a significant leap from the conventional 66.4%. This innovation enables faster charging, higher brightness, and up to 14 hours of continuous lighting, ensuring consistent performance in any weather, rain or shine.


Smart Control with Alexa and Google Assistant

Designed for smart home integration, the Linkind SL5C is compatible with Alexa and Google Assistant when paired with a Linkind BLE Mesh Hub. Users can control the light via voice commands or directly through the Alexa and Google Home apps, adjusting brightness, colors, and white temperature with ease. Additionally, the AiDot app offers advanced customization, making it simple to tailor lighting settings to different moods and occasions.

Versatile Illumination for Any Outdoor Setting

From landscaping accents to pathway lighting, the Linkind SL5C enhances outdoor spaces with rich colors and consistent brightness. Its adaptable design allows for ground placement or vertical mounting on fences, walls, and garden structures, making it ideal for creating inviting entryways, accentuating architectural elements, or illuminating hard-to-reach corners. Even in challenging weather conditions, the SL5C delivers reliable, vibrant lighting, elevating the ambiance of any outdoor environment.

Intelligent Features for a Smarter Lighting Experience

The Linkind SL5C goes beyond traditional outdoor lighting with 14 preset scenes and customizable options, enabling dynamic light shows that enhance any setting. With support for up to 32 units in synchronized operation, users can achieve a seamless, cohesive lighting effect across their entire yard. Smart scheduling ensures the lights turn on at dusk and off at dawn automatically, or follow personalized routines to match any lifestyle. Effortless grouping and synchronization features allow users to apply settings across multiple lights with just a few taps, making smart outdoor lighting more convenient and intuitive than ever.


Choose Your Ideal Linkind Smart Solar Spotlight

Linkind SL5C

Linkind SL5

Maximum Power Point Tracking

×

Run Time

Up to 14 hours in energy-saving mode.

Up to 12 hours in energy-saving mode.

Luminance Detection

Light Mode

Motion Detection

×

Lumens

150 Lumen

250 Lumen

Color

RGB

RGBTW

Waterproof Rating

IP67

IP65

Preset Scenes

43+

43+

Group Control

Sync with Music

Adjustable Brightness

1%-100%

1%-100%

Mounting Type

Wall Mount/Ground Insert

Wall Mount/Ground Insert

With its advanced MPPT charging technology, ensuring optimal performance in any weather, and up to 14 hours of runtime, SL5C is suitable for use in all regions, especially ideal for users in areas with limited sunlight. However, for environments with more favorable weather conditions, the Linkind SL5 remains a strong alternative.

Price and Availability

The Linkind SL5C will officially launch on Linkind.com on April 17, 2025. It is also available now on Amazon. To celebrate the launch, both Linkind.com and Amazon will offer a 30% limited-time discount from April 17 to April 30. During this promotional period, the 2-pack will be priced at $24.49, and the 8-pack at $90.99.

About Linkind

Linkind, a brand of AiDot, is passionate about lighting your spaces in intelligent and meaningful ways, all while adopting the dedication to innovation and eco-conscious design instilled by its parent company, and overall ecosystem, AiDot. These tenants have guided Linkind from the start and are why they are now able to proudly offer solutions to match any and all residential scenes, such as smart solar-powered solutions that light the path to your home, TV backlighting that takes movie night to the next level, and easy-to-use everyday lighting with unmatched levels of user convenience. Linkind is lighting the way to a brighter tomorrow.

 

ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone

Showcasing at ASCRS 2025:

  • More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons.
  • ZEISS MEL 90 broadens refractive treatment portfolio: U.S. availability of both the ZEISS MEL 90 and ZEISS VISUMAX 800 extends the company’s LVC market leadership with treatments for myopia, hyperopia, and mixed astigmatism.
  • Enhanced cataract portfolio with DORC and FCI: Showcasing cataract solutions from DORC and FCI for the first time in the ZEISS booth #1501.

JENA, Germany and DUBLIN, Calif., April 17, 2025 /PRNewswire/ — ZEISS Medical Technology will celebrate the rapid adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25 – 27 in Los Angeles, CA. ZEISS marks a major milestone in the U.S. with more than 2 million digitally planned cases using the ZEISS VERACITY Surgery Planner,1 one of the leading digital planning solutions for cataract surgery, which serves as a testament to the growing number of surgeons discovering the benefits of digital workflows in the delivery of patient care and treatments.

ZEISS VERACITY Surgery Planner
ZEISS VERACITY Surgery Planner

“The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices,” says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and ongoing commitment to improving patient care across both the cataract and refractive markets.”

Additionally, the ZEISS Refractive Workflow will showcase for the first time both the VISUMAX® 800 with SMILE® pro from ZEISS and the MEL® 90 from ZEISS, helping to further broaden a surgeon’s refractive business with improved patient attraction and positive clinical outcomes. Lastly, for the first time, DORC and FCI, both ZEISS companies, are set to present their portfolio of cataract surgical solutions in the ZEISS booth, showcasing the extended benefits of ZEISS’s surgical portfolio.

More than 2 million cases planned using ZEISS VERACITY Surgery Planner reflects growing digital adoption by U.S. cataract surgeons

ZEISS VERACITY Surgery Planner is one of the top digital planning solutions for cataract surgery in the U.S. today with thousands of users logging in to plan their surgical cases, pulling data from most modern EMRs, 19 different diagnostic devices, and optional data sources like patient questionnaires, in order to make data-driven informed decisions designed to drive better patient outcomes in clinics and ORs.

At ASCRS, ZEISS will celebrate the significant milestone of its cloud-based ZEISS VERACITY Surgery Planner, with more than 2 million cases planned. A recent study showed that with the ZEISS Cataract Workflow powered by ZEISS VERACITY Surgery Planner, surgeons and staff can save up to 60% of their time per eye compared to traditional paper planning.2

Kerry Solomon, MD, from Carolina Eye Care Physicians, one of the creators of VERACITY prior to its acquisition by ZEISS in 2017, says, “Today we’re up to 2 million plans, unbelievable! When we first started developing this solution, I absolutely envisioned we’d get to where we are today, and I’m thrilled with where we’re at!”

In addition to proven efficiency gains, new research abstracts presented at this year’s ASCRS showcase excellent refractive accuracy and clinical outcomes when adopting the ZEISS Cataract Workflow:

  1. Steven C. Schallhorn, MD, ABO, will present a clear benefit of reducing postoperative astigmatism by implanting toric IOLs in patients with lower preoperative corneal astigmatism, leveraging cataract outcomes obtained from VERACITY Surgery Planner’s database of 50,850 eyes with preoperative corneal astigmatism between 0.75D and 1.50D.
  2. Luke Rebenitsch, MD, ABO, will present a comparison of refractive outcomes in a large cohort of 49,057 eyes undergoing cataract surgery with toric IOL implantation where the use of the ZEISS CALLISTO eye system resulted in significant improvements in terms of post-op refractive outcomes compared to a manual marking approach.
  3. Kamran M. Riaz, MD, ABO, will present an analysis of the refractive accuracy of two biometers in a cohort of 222 eyes with prior laser vision correction and implantation of toric multifocal IOLs, highlighting the significantly better performance of total keratometry with the IOLMaster 700.

Enhanced refractive treatment portfolio enables a higher standard of refractive patient care with both the ZEISS VISUMAX 800 and ZEISS MEL 90

ZEISS continues to set high standards in refractive patient care in the U.S. with the availability of both the ZEISS VISUMAX 800 and ZEISS MEL 90. For the first time, the ZEISS MEL 90 will be showcased in the U.S. at ASCRS, extending ZEISS’s LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.

“The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. I am particularly impressed by the system’s ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. This approval marks an exciting chapter for surgeons and patients alike,” says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO (USA).

The MEL® 90 from ZEISS aims to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon’s refractive business with improved patient attraction and positive clinical outcomes.

The ZEISS VISUMAX 800 with ZEISS SMILE pro software enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.3 The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise.

Showcasing the benefits of ZEISS’s surgical portfolio to help meet the evolving clinical challenges of surgeons in the U.S.

ZEISS will showcase for the first time together in the ZEISS booth key solutions from DORC and FCI.  This will feature the DORC EVA NEXUS surgical system for cataract and phaco-vitrectomy surgeries. It will also include the DORC VisionBlue® anterior stain, a trusted choice in more than 10 million cataract surgeries since its introduction. As the only FDA-approved trypan blue stain for anterior applications, it is also authorized for staining Descemet’s membrane and trabecular meshwork.  Additionally, the ZEISS booth will feature the FDA-approved Eyejet® 20C from Morcher®, built on the gold standard preloaded Eyejet® system and designed to prevent toric IOLs rotation, providing maximum toric benefits.

ZEISS will showcase its latest offerings and new innovations at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25-27, 2025, in Los Angeles, CA, at booth #1501.

For more information, visit www.zeiss.com/med

1 Data on file.
2 Gujral, Tarika, and John Hovanesian. “Cataract Surgical Planning Using Online Software vs Traditional Methods.” Clinical Ophthalmology (Auckland, N.Z.), U.S. National Library of Medicine, 28 July 2021.
3 Data on file, myopia with optical zone 6.5 mm. 

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals’ content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. 

Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.meditec@zeiss.com

Contact for the press
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com

www.zeiss.com/newsroom          

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

ZEISS MEL 90 Excimer Laser
ZEISS MEL 90 Excimer Laser